Hebei Virus Outbreak Underscores the CCP’s Lies About an Affluent China
Commentary
The surge of COVID-19 cases in Hebei Province since the year began has now become a new focal point of China’s epidemic.
Up to now, Shijiazhuang, Xingtai, and Langfang the cities with the most CCP virus infections have implemented “sealed off management.” Thousands of villagers have been taken away for “centralized isolation.” It appears the Chinese regime is avoiding the term “lockdown” in an attempt to downplay the severity of the outbreak.
A major feature of this outbreak in Hebei is that it is concentrated in rural areas. This goes against experts’ previous hypothesis that the risk of transmission in rural areas is less than in urban cities.
(UPDATED) For patients with acute ischemic strokes caused by large-vessel occlusions, forgoing IV thrombolytics before mechanical thrombectomy may be a viable option, according to the results of two trials published online this week in
JAMA.
In the DEVT trial, taking patients directly to the cath lab resulted in noninferior 90-day functional outcomes compared with the guideline-recommended approach of administering IV alteplase before the intervention, lead author Wenjie Zi, MD (Xinqiao Hospital and The Second Affiliated Hospital, Chongqing, China), and colleagues report.
And in the SKIP trial, which was initially presented at the International Stroke Conference last year, functional outcomes were similar with the two strategies. The trial, however, did not establish the noninferiority of skipping IV thrombolytics, a result attributed to higher-than-expected rates of recanalization and favorable outcomes.
email article
Two small trials added to the evidence that some stroke patients could fare well going straight to mechanical thrombectomy without IV thrombolysis, though the studies were confined to Asian populations and non-inferiority was not shown in the strictest sense.
For patients with acute ischemic stroke due to large vessel occlusion, results were inconclusive (but somewhat favorable) for a strategy of skipping the IV tissue plasminogen activator (tPA) usually recommended prior to mechanical thrombectomy in the Japanese SKIP trial.
However, a similar strategy did prove to be non-inferior to combined thrombectomy and IV tPA in the Chinese DEVT trial.
Shenyang City in Northeastern China Becomes CCP Virus Hotspot
COVID-19 cases have ballooned in Shenyang, the capital of northeastern China’s Liaoning Province, as authorities struggle to contain the outbreak. Residents told The Epoch Times that infections are being underreported by the local government.
On Dec. 30, authorities confirmed that at least three medical staff in Shenyang tested positive. One was a nurse from Pukang Hospital (diagnosed on Dec. 26), and the other two were a nurse and a physician assistant, both from Xiushui Clinic (diagnosed on Dec. 28).
A notice issued by the Shenyang Municipal Health Commission said the three infected staffers are all associated with a new patient surnamed Yin, diagnosed on Dec. 23. Currently, the four hospitals Yin visited are all under lockdown, including Xiushui Clinic, Shenyang Pukang Hospital, the north district of Second Affiliated Hospital of Shenyang Medical College, and Shenyang No. 4 People’s Hospital.
ACC Names Jian an Wang Inaugural Editor-in-Chief of JACC: Asia Dec 21, 2020
JACC: Asia, the newest addition to the
JACC Journals portfolio and the first region-specific cardiovascular journal with original peer-reviewed content.
Wang serves as the chair of the Heart Center at the Second Affiliated Hospital at Zhejiang University School of Medicine in China and is also a professor and associate dean at Zhejiang University School of Medicine. A leading interventional cardiologist, Wang has spearheaded the efforts in establishing and developing one of the largest valvular heart disease programs in Asia. He has also developed several innovative devices for valvular interventions, in collaboration with engineers, cardiovascular colleagues and manufacturers, that have been approved by the China Food and Drug Administration. His research work focuses on improving the efficacy of stem cell implantation in infarcted myocardium through hypoxemic preconditioning, which has bee